Pill could replace shots for MDS patients, cutting hospital trips
NCT ID NCT04806906
First seen May 13, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This study tested an oral chemotherapy pill (CC-486) in 11 older adults with higher-risk myelodysplastic syndromes (MDS) who had already responded to injected azacitidine. The goal was to see if switching to the pill could maintain their response and improve quality of life by reducing the need for frequent hospital visits. The study monitored safety, response maintenance, and patient-reported well-being.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOU Careggi- University of Florence
Florence, 50134, Italy
Conditions
Explore the condition pages connected to this study.